Patents by Inventor Olivier Lèger

Olivier Lèger has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIBODIES TO IL-15
    Publication number: 20190315853
    Abstract: The present invention relates to antibodies binding IL-15, in particular humanized antibodies. In particular, the anti-IL-15 antibodies according to the invention are able to neutralize IL-15 activity and are useful in the prevention and/or treatment of an autoimmune disease and/or inflammatory disorder, a malignancy, transplant rejection, metabolic condition and/or an infectious disease caused by parasitic, viral or bacterial pathogens.
    Type: Application
    Filed: May 24, 2019
    Publication date: October 17, 2019
    Inventors: ALAIN VICARI, OLIVIER LEGER
  • ANTI-GITR ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20190309082
    Abstract: The present disclosure provides antibodies that specifically bind to human glucocorticoid-induced TNFR family related receptor (GITR) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human GITR and modulate GITR activity, e.g., enhance, activate or induce GITR activity, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as cancer and infectious diseases, by administering an antibody that specifically binds to human GITR and modulates GITR activity e.g., enhances, activates or induces GITR activity.
    Type: Application
    Filed: March 15, 2019
    Publication date: October 10, 2019
    Inventors: Volker SEIBERT, Olivier LÉGER, Marc VAN DIJK, Taha MERGHOUB, David SCHAER, Gerd RITTER, Takemasa TSUJI
  • Antibodies specific for MMP9
    Patent number: 10364296
    Abstract: The present invention relates to new proteins that bind to MMP9 and comprise at least one fragment of a heavy chain variable region and/or at least one fragment of a light chain variable region of an antibody. In particular, the MMP9 binding proteins according to the invention are able to neutralize MMP9 activity and are useful in the prevention and/or treatment of inflammatory and/or autoimmune diseases or cancers. In particular, the MMP9 binding proteins according to the invention are useful in diagnosis of MMP9-related disorders.
    Type: Grant
    Filed: August 13, 2015
    Date of Patent: July 30, 2019
    Assignees: CALYPSO BIOTECH SA, MERCK PATENT GMBH
    Inventors: Yolande Chvatchko Missotten, Laurence Goffin, Olivier Leger, Steven M. Dunn, Christine Power, Kinsey Maundrell
  • Antibodies to IL-15
    Patent number: 10301384
    Abstract: The present invention relates to antibodies binding IL-15, in particular humanized antibodies. In particular, the anti-IL-15 antibodies according to the invention are able to neutralize IL-15 activity and are useful in the prevention and/or treatment of an autoimmune disease and/or inflammatory disorder, a malignancy, transplant rejection, metabolic condition and/or an infectious disease caused by parasitic, viral or bacterial pathogens.
    Type: Grant
    Filed: July 1, 2015
    Date of Patent: May 28, 2019
    Assignee: CALYPSO BIOTECH SA
    Inventors: Alain Vicari, Olivier Leger
  • BISPECIFIC ANTIBODIES TARGETING EGFR AND HER2
    Publication number: 20190153104
    Abstract: The present disclosure relates to bispecific antibodies targeting EGFR and HER2, and methods for the production of these antibodies. The bispecific antibodies consist of one complete antibody on which two VH-VL chains are attached via a linker to each NH terminal region of both VH chains of the antibody. The bispecific antibodies constructed use the amino acid sequences of the heavy chain (VH) and the light chain (VL) variable regions of two monoclonal antibodies targeting EGFR and HER2, namely cetuximab and trastuzumab, respectively.
    Type: Application
    Filed: April 28, 2017
    Publication date: May 23, 2019
    Inventors: EUGENE ZHUKOVSKY, OLIVIER LEGER, PIERRE-EMMANUEL GERARD, ANDRE PELEGRIN, CHRISTEL LARBOURET
  • Anti-GITR antibodies and methods of use thereof
    Patent number: 10280226
    Abstract: The present disclosure provides antibodies that specifically bind to human glucocorticoid-induced TNFR family related receptor (GITR) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human GITR and modulate GITR activity, e.g., enhance, activate or induce GITR activity, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as cancer and infectious diseases, by administering an antibody that specifically binds to human GITR and modulates GITR activity e.g., enhances, activates or induces GITR activity.
    Type: Grant
    Filed: October 30, 2018
    Date of Patent: May 7, 2019
    Assignees: Agenus Inc., Memorial Sloan-Kettering Cancer Center, Ludwig Institute for Cancer Research Ltd
    Inventors: Volker Seibert, Olivier Léger, Marc Van Dijk, Taha Merghoub, David Schaer, Gerd Ritter, Takemasa Tsuji
  • AMINO ACID SEQUENCES DIRECTED AGAINST IL-17A, IL-17F AND/OR IL-17A/F AND POLYPEPTIDES COMPRISING THE SAME
    Publication number: 20190100584
    Abstract: The present disclosure relates to amino acid sequences that are directed against (as defined herein) any of IL-17A, IL-17F and/or IL-17A/F including combinations thereof, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.
    Type: Application
    Filed: June 7, 2018
    Publication date: April 4, 2019
    Applicant: Merck Patent GmbH
    Inventors: Heidi ROMMELAERE, Joost Alexander KOLKMAN, Michael John Scott SAUNDERS, Ann UNION, Yolande CHVATCHKO, Amanda E.I. PROUDFOOT, Alain VICARI, Denis BRUNIQUEL, Laurent CHEVALET, Olivier LEGER
  • Anti-GITR Antibodies and Methods of Use Thereof
    Publication number: 20190062446
    Abstract: The present disclosure provides antibodies that specifically bind to human glucocorticoid-induced TNFR family related receptor (GITR) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human GITR and modulate GITR activity, e.g., enhance, activate or induce GITR activity, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as cancer and infectious diseases, by administering an antibody that specifically binds to human GITR and modulates GITR activity e.g., enhances, activates or induces GITR activity.
    Type: Application
    Filed: October 30, 2018
    Publication date: February 28, 2019
    Inventors: Volker SEIBERT, Olivier LÉGER, Marc VAN DIJK, Taha MERGHOUB, David SCHAER, Gerd RITTER, Takemasa TSUJI
  • Anti-GITR Antibodies and Methods of Use Thereof
    Publication number: 20190010239
    Abstract: The present disclosure provides antibodies that specifically bind to human glucocorticoid-induced TNFR family related receptor (GITR) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human GITR and modulate GITR activity, e.g., enhance, activate or induce GITR activity, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as cancer and infectious diseases, by administering an antibody that specifically binds to human GITR and modulates GITR activity e.g., enhances, activates or induces GITR activity.
    Type: Application
    Filed: April 25, 2018
    Publication date: January 10, 2019
    Inventors: Ana M. GONZALEZ, Nicholas S. WILSON, Dennis J. UNDERWOOD, Volker SEIBERT, Olivier LÉGER, Marc VAN DIJK, Roberta ZAPPASODI, Taha MERGHOUB, Jedd David WOLCHOK, David SCHAER, Gerd RITTER, Takemasa TSUJI
  • Anti-GITR antibodies and methods of use thereof
    Patent number: 10155818
    Abstract: The present disclosure provides antibodies that specifically bind to human glucocorticoid-induced TNFR family related receptor (GITR) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human GITR and modulate GITR activity, e.g., enhance, activate or induce GITR activity, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as cancer and infectious diseases, by administering an antibody that specifically binds to human GITR and modulates GITR activity e.g., enhances, activates or induces GITR activity.
    Type: Grant
    Filed: May 28, 2015
    Date of Patent: December 18, 2018
    Assignees: Agenus Inc., Memorial Sloan-Kettering Cancer Center, Ludwig Institute for Cancer Research Ltd.
    Inventors: Volker Seibert, Olivier Léger, Marc Van Dijk, Taha Merghoub, David Schaer, Gerd Ritter, Takemasa Tsuji
  • Anti-GITR Antibodies and Methods of Use Thereof
    Publication number: 20180355051
    Abstract: The present disclosure provides antibodies that specifically bind to human glucocorticoid-induced TNFR family related receptor (GITR) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human GITR and modulate GITR activity, e.g., enhance, activate or induce GITR activity, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as cancer and infectious diseases, by administering an antibody that specifically binds to human GITR and modulates GITR activity e.g., enhances, activates or induces GITR activity.
    Type: Application
    Filed: April 25, 2018
    Publication date: December 13, 2018
    Inventors: Ana M. GONZALEZ, Nicholas S. WILSON, Dennis J. UNDERWOOD, Volker SEIBERT, Olivier LÉGER, Marc VAN DIJK, Roberta ZAPPASODI, Taha MERGHOUB, Jedd David WOLCHOK, David SCHAER, Gerd RITTER, Takemasa TSUJI
  • NEUTRALIZING ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20180282426
    Abstract: This invention provides monoclonal antibodies that recognize the Toll-like Receptor 4/MD-2 receptor complex, and monoclonal antibodies that recognize the TLR4/MD2 complex as well as TLR4 when not complexed with MD-2. The invention further provides methods of using the monoclonal antibodies as therapeutics. This invention also provides soluble chimeric proteins, methods of expressing and purifying soluble chimeric proteins, and methods of using soluble chimeric proteins as therapeutics, in screening assays and in the production of antibodies.
    Type: Application
    Filed: June 14, 2018
    Publication date: October 4, 2018
    Inventors: Greg Elson, Olivier Leger
  • Anti-GITR Antibodies and Methods of Use Thereof
    Publication number: 20180244793
    Abstract: The present disclosure provides antibodies that specifically bind to human glucocorticoid-induced TNFR family related receptor (GITR) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human GITR and modulate GITR activity, e.g., enhance, activate or induce GITR activity, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as cancer and infectious diseases, by administering an antibody that specifically binds to human GITR and modulates GITR activity e.g., enhances, activates or induces GITR activity.
    Type: Application
    Filed: April 25, 2018
    Publication date: August 30, 2018
    Inventors: Ana M. GONZALEZ, Nicholas S. WILSON, Deninis J. UNDERWOOD, Volker SEIBERT, Olivier LÉGER, Marc VAN DIJK, Roberta ZAPPASODI, Taha MERGHOUB, Jedd David WOLCHOK, David SCHAER, Gerd RITTER, Takemasa TSUJI
  • Neutralizing antibodies and methods of use thereof
    Patent number: 10023646
    Abstract: This invention provides monoclonal antibodies that recognize the Toll-like Receptor 4/MD-2 receptor complex, and monoclonal antibodies that recognize the TLR4/MD2 complex as well as TLR4 when not complexed with MD-2. The invention further provides methods of using the monoclonal antibodies as therapeutics. This invention also provides soluble chimeric proteins, methods of expressing and purifying soluble chimeric proteins, and methods of using soluble chimeric proteins as therapeutics, in screening assays and in the production of antibodies.
    Type: Grant
    Filed: January 5, 2017
    Date of Patent: July 17, 2018
    Assignee: NovImmunie S.A.
    Inventors: Greg Elson, Olivier Leger
  • ANTI-CD3 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20180194842
    Abstract: The present invention is related to antibodies directed to the antigen CD3 and uses of such antibodies. In particular, the present invention provides fully human monoclonal antibodies directed to CD3. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3, are provided. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also provided.
    Type: Application
    Filed: December 21, 2017
    Publication date: July 12, 2018
    Inventors: Bernard MACH, Yann DEAN, Marie KOSCO-VILBOIS, Greg ELSON, Nicolas FISCHER, Olivier LEGER
  • Polypeptides that bind to IL-17A, IL-17F and/or IL17-A/F and method of treatment using same
    Patent number: 10017568
    Abstract: The present disclosure relates to amino acid sequences that are directed against (as defined herein) any of IL-17A, IL-17F and/or IL-17A/F including combinations thereof, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.
    Type: Grant
    Filed: May 4, 2012
    Date of Patent: July 10, 2018
    Assignee: Merck Patent GmbH
    Inventors: Heidi Rommelaere, Joost Alexander Kolkman, Michael John Scott Saunders, Ann Union, Yolande Chvatchko, Amanda E. I. Proudfoot, Alain Vicari, Denis Bruniquel, Laurent Chevalet, Olivier Leger
  • ANTI-IL-6/IL-6R ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20180086839
    Abstract: This invention provides fully human monoclonal antibodies that recognize the IL-6/IL-6R complex. The invention further provides methods of using such monoclonal antibodies as a therapeutic, diagnostic, and prophylactic.
    Type: Application
    Filed: November 27, 2017
    Publication date: March 29, 2018
    Inventors: Walter FERLIN, Marie KOSCO-VILBOIS, Greg ELSON, Olivier LEGER, Florence GULHOT
  • Anti-CD3 antibodies and methods of use thereof
    Patent number: 9850304
    Abstract: The present invention is related to antibodies directed to the antigen CD3 and uses of such antibodies. In particular, the present invention provides fully human monoclonal antibodies directed to CD3. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3, are provided. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also provided.
    Type: Grant
    Filed: October 8, 2013
    Date of Patent: December 26, 2017
    Assignee: NOVIMMUNE S.A.
    Inventors: Bernard Mach, Yann Dean, Marie Kosco-Vilbois, Greg Elson, Nicolas Fischer, Olivier Leger
  • Anti-IL-6/IL-6R antibodies
    Patent number: 9828430
    Abstract: This invention provides fully human monoclonal antibodies that recognize the IL-6/IL-6R complex. The invention further provides methods of using such monoclonal antibodies as a therapeutic, diagnostic, and prophylactic.
    Type: Grant
    Filed: January 12, 2016
    Date of Patent: November 28, 2017
    Assignee: NOVIMMUNE S.A.
    Inventors: Walter Ferlin, Marie Kosco-Vilbois, Greg Elson, Olivier Leger, Florence Guilhot
  • Fc RECEPTOR-BINDING POLYPEPTIDES WITH MODIFIED EFFECTOR FUNCTIONS
    Publication number: 20170298129
    Abstract: Disclosed are processes for producing a variant polypeptide (e.g. antibodies) having modified binding characteristics for human Fc gamma receptor IIA (CD32A) leading to increased inhibition of proinflammatory mediators while retaining binding to a target antigen via its Fv portion, which processes comprise altering the polypeptides by substitution of at least two amino acid residues at EU position 325, 326 or 328 of a human IgG CH2 region for a sequence selected from SAAF, SKAF, NAAF and NKAF. The polypeptides that can be generated according to the methods of the invention are highly variable, and they can include antibodies and fusion proteins that contain an Fc region or a biologically active portion thereof.
    Type: Application
    Filed: June 26, 2017
    Publication date: October 19, 2017
    Inventors: Greg Elson, Olivier Leger